1. A compound containing a Q-L-Y structure； wherein Q is a glucagon superfamily peptide； Y is a GR ligand that activates a glucocorticoid receptor with an EC of about 1 μM or less and has a molecular weight of up to about 1000 daltons； and L is a linker or link. 2. The compound of claim 1, wherein Q exhibits at least 0.1% native GLP-1 activity against the GLP-1 receptor, at least 0.1% native glucagon activity against the glucagon receptor, at least , 0.1% activity of native GIP against the GIP receptor, or a combination thereof. 3. A compound according to claim 1, wherein Q has an EC for the GLP-1 receptor within a 10-fold ECY value for a glucocorticoid receptor, an EC for a glucagon receptor within a 10-fold ECY for a glucocorticoid receptor, an EC for a GIP receptor in within 10 times the ECY for the glucocorticoid receptor or a combination thereof. 4. A compound according to claim 1, wherein Y is a compound of the formula Formula where each of R, R, R, R, R, R and R independently is a moiety that permits agonistic or antagonistic activity when the compound of formula C is bound to a nuclear hormone receptor or glucocorticoid receptor or contribute to it； and each dotted line represents an optional double bond； and Y conjugated to L at position 3 or 17 Y.5. The compound of claim 4, wherein Y is cortisol or a derivative thereof. The compound of claim 5, wherein the cortisol or its derivative is selected from the group consisting of cortisol, cortisone acetate, beclomethasone, prednisone, prednisolone, methyl prednisone1. Соединение, содержащее структуру Q-L-Y；где Q представляет собой пептид глюкагонового суперсемейства；Y представляет собой GR-лиганд, который активирует глюкокортикоидный рецептор с ECприблизительно 1 мкМ или меньше и имеет молекулярный вес вплоть до приблизительно 1000 дальтон； иL представляет собой линкер или связь.2. Соединение по п. 1, где Q проявляет, по меньшей мере, 0,1% активность нативного GLP-1 в отношении GLP-1-рецептора, по меньшей мере,
